electroCore gives update on gammaCore Sapphire amid Emergency Use Authorization electroCore announced more information about availability, distribution and pricing for gammaCore Sapphire CV non-invasive vagus nerve stimulation, nVNS, therapy under its Emergency Use Authorization, EUA. The EUA allows for the use of gammaCore Sapphire(TM) CV at home or in a healthcare setting to acutely treat adult patients with known or suspected COVID-19 who are experiencing exacerbation of asthma-related dyspnea and reduced airflow, and for whom approved drug therapies are not tolerated or provide insufficient symptom relief. "We are pleased to be ready to make gammaCore Sapphire CV available to treat people with known or suspected COVID-19 who are experiencing exacerbation of asthma-related breathing difficulty," said Dan Goldberger, Chief Executive Officer of electroCore. "Our goal is to make this process as simple as possible for all of the patients, physicians and hospitals that would like to use gammaCore Sapphire CV, and we have engaged Premier Pharmacy Services, a national specialty pharmacy, to support its distribution." Stephen Samuel, Chief Executive Officer of Premier Pharmacy Services, stated, "At Premier, our mission every day is to help our patients manage complex diseases, and we are pleased to partner with electroCore to offer gammaCore Sapphire CV therapy to COVID-19 patients in need."
News 
Market Data 
Discover 
